

ACTIVE PHARMACEUTICAL INGREDIENTS

COMMERCIALY AVAILABLE

INN	Quality	CEP / BR DMF / CN DMF / US DMF / JP DMF / EU DMF
Allopurinol	EP/JP	JP DMF / CEP
Amlodipine besilate	EP	CN DMF / BR DMF / CEP
Bisoprolol fumarate	EP	CEP
Carvedilol form II	EP	CEP
Chlorpromazine HCl	EP	EU DMF / BR DMF / JP DMF / CEP
Clomiphene citrate	EP	EU DMF
Crotamiton	EP/USP/CP	CN DMF / US DMF / CEP
Donepezil HCl form I	USP/EP	EU DMF
Ethacrynic acid	EP/USP	CEP / US DMF
Ketoprofen	EP	CEP
Levomopromazine maleate	EP	EU DMF / BR DMF / CEP
Methyldopa	EP	CEP
Nifedipine	EP	EU DMF
Nitrendipine	EP	CEP
Promethazine HCl	EP/USP	US DMF / BR DMF / CEP
Quetiapine fumarate	EP	EU DMF / CEP
Ramipril	EP	CEP
Rivaroxaban	EP	EU DMF
Tofisopam	JP/ICH	JP DMF / EU DMF

SOON COMMERCIALY AVAILABLE

INN	Quality	DMF, CEP
Duloxetine	EP	CEP (2024 Q4)
Levocetirizine diHCl	EP	CEP (2025 Q1)

All the activities (development, testing, production) concerning the active pharmaceutical ingredients listed in the API product catalog are performed in countries where such activities are not prevented by third parties' rights, especially patent rights, and in compliance with the IP laws of the respective country. None of the products will be offered / supplied to countries in which these activities might be prevented by valid IP rights. However, the final legal responsibility lies exclusively on the buyer. Egis does explicitly exclude any and all legal responsibility for the correctness and for the use of the information in the API product catalog.